SEC Form 4 · accession 0001615219-16-000124
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Wessel
Officer — Chief Medical Officer
Period of report
Mar 11, 2016
Accepted (ET)
Mar 15, 2016 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001615219
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2016 | P | 12,000 | $7.15 | A | 49,064 | D | |
| Common StockF2 | Mar 14, 2016 | P | 8,000 | $9.13 | A | 57,064 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $6.91 to $7.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- F2The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $7.69 to $9.58. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.